BYU

Abstract by David Foote

Personal Infomation


Presenter's Name

David Foote

Degree Level

Undergraduate

Co-Authors

Kevin Foote

Abstract Infomation


Department

Chemistry and Biochemistry

Faculty Advisor

Richard Watt

Title

Triferic as a Treatment for Anemia of Chronic Inflammation

Abstract

Anemia of chronic inflammation (ACI) affects 15 million US patients. Inflammation releases hepcidin that degrades the Fe-exporter ferroportin trapping Fe in the liver and blocking Fe delivery to the bone marrow. A method to load Fe into transferrin (Tf) is needed to treat anemia. Rockwell Medical developed a Fe drug (Triferic) for ACI patients. Triferic is Fe3+ coordinated by citrate and pyrophosphate. The monomeric Fe in Triferic might be a substrate for transferrin. Our lab developed a transferrin Fe-loading assay to evaluate Triferic as a substrate for transferrin. Our preliminary work showed that Triferic effectively loads Fe into transferrin. We observed that pyrophosphate also enhances iron binding in transferrin.